Nitrous Oxide, Usp (nitrous oxide)

Where it stands

The records show Nitrous Oxide, USP (nitrous oxide) as approved in the US. The sponsor is listed as Linde Gas Equip. The single milestone is an FDA approval dated 2026-08-09 under NDA221892, with the dosage form recorded as gas. The source is marked official.

The records do not give an indication, a therapeutic area, a strength or any labeled conditions of use. The product's intended clinical use therefore cannot be described from this data. No CHMP opinion date is recorded, which is consistent with a US-only entry.

Regulatory pathway and designations

The approval is recorded under a New Drug Application, NDA221892. An NDA is the standard US route for marketing a drug, and approval means FDA concluded the application met the statutory standards for the product as described in its labeling. The records do not say whether this was a full application or an abbreviated or reference-based one, so the specific NDA subtype is unknown.

No designations are recorded. There is no orphan, fast track, breakthrough, priority review or similar status in the data. The records contain no review timeline, advisory committee activity, PDUFA goal date or complete response history. Nothing can be said about how the review ran.

Safety and pharmacovigilance

The records contain no safety information, such as labeled warnings, contraindications, adverse-reaction data, a REMS or postmarketing requirements. Any assessment of this product's risk profile would need the approved prescribing information and FDA review documents.

As a general point, the holder of an approved US NDA has standing postmarketing obligations. These include adverse event reporting to FDA and periodic reporting. This is general regulatory procedure and not a finding about this product. The records do not say whether any product-specific commitments were attached.

What to watch

The first step is to retrieve the approved labeling and the approval letter for NDA221892. These would confirm the indication, the presentations and any postmarketing commitments. They would also show whether the application relied on prior FDA findings or on new data.

The records show no further milestones after the approval. Useful follow-up includes any labeling supplements, changes to the sponsor's product listing, and any FDA safety communications. None of these appear in the current data.